fenfluramine has been researched along with Hyperlipidemias in 12 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals." | 4.78 | [Mode of action of benfluorex. Recent data]. ( Brindley, DN, 1992) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "The syndrome is characterized by insulin insensitivity and an increased control of metabolism by cortisol." | 2.38 | Neuroendocrine regulation and obesity. ( Brindley, DN, 1992) |
| "Benfluorex-treated animals showed significant decreases in glucose intolerance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia, and plasma LDL- and VLDL-cholesterol, with no evidence of aortic atheroma." | 1.30 | Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus). ( Bennani, N; El Madani, T; Hadjiisky, P; Marquié, G; Pieraggi, MT; Ravel, D; Seguin, L; Solera, ML, 1998) |
| "The problem of obesity is not well dealt with in the ordinary diabetes clinic." | 1.25 | A year's experience in a clinic for obese diabetics. ( Goldblatt, R; Jackson, WP; Movsowitz, F, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nau, JY | 1 |
| Després, JP | 1 |
| Lemieux, S | 1 |
| Lamarche, B | 1 |
| Prud'homme, D | 1 |
| Moorjani, S | 1 |
| Brun, LD | 1 |
| Gagné, C | 1 |
| Lupien, PJ | 1 |
| Bremer, JM | 1 |
| Scott, RS | 1 |
| Lintott, CJ | 1 |
| Brindley, DN | 3 |
| Marquié, G | 1 |
| El Madani, T | 1 |
| Solera, ML | 1 |
| Pieraggi, MT | 1 |
| Hadjiisky, P | 1 |
| Ravel, D | 1 |
| Seguin, L | 1 |
| Bennani, N | 1 |
| Greenway, FL | 1 |
| Ryan, DH | 1 |
| Bray, GA | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Jackson, WP | 1 |
| Movsowitz, F | 1 |
| Goldblatt, R | 1 |
| Riveline, B | 1 |
| Duhault, J | 1 |
| Boulander, M | 1 |
| Beregi, L | 1 |
| Ranquin, R | 1 |
4 reviews available for fenfluramine and Hyperlipidemias
| Article | Year |
|---|---|
The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications.
Topics: Adipose Tissue; Cardiovascular Diseases; Fenfluramine; Humans; Hyperlipidemias; Insulin Resistance; | 1995 |
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
Neuroendocrine regulation and obesity.
Topics: Animals; Diabetes Complications; Endocrine Glands; Fenfluramine; Humans; Hydrocortisone; Hyperlipide | 1992 |
[Mode of action of benfluorex. Recent data].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids; Female; Fenflu | 1992 |
3 trials available for fenfluramine and Hyperlipidemias
| Article | Year |
|---|---|
Dexfenfluramine reduces cardiovascular risk factors.
Topics: Apolipoproteins B; Body Mass Index; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Choleste | 1994 |
780SE in the management of disorders of lipid and glucose metabolism.
Topics: Adult; Aged; Diabetes Mellitus; Female; Fenfluramine; Humans; Hyperlipidemias; Male; Middle Aged; Ob | 1975 |
Effects of benfluorex on patients with endogenous hypertriglyceridaemia.
Topics: Adult; Aged; Body Weight; Double-Blind Method; Female; Fenfluramine; Humans; Hyperlipidemias; Hypoli | 1987 |
5 other studies available for fenfluramine and Hyperlipidemias
| Article | Year |
|---|---|
[What were the indications for the Mediator in 1979?].
Topics: Anxiety; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; France; Heart Valve Diseases | 2011 |
Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus).
Topics: Animal Nutritional Physiological Phenomena; Animals; Aorta; Arteriosclerosis; Body Weight; Cholester | 1998 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
A year's experience in a clinic for obese diabetics.
Topics: Adult; Aged; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diet, Reducin | 1975 |
Pharmacological effects of 780SE (992) on hyperlipidaemic and obese rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Female; Fenfluram | 1975 |